NEW YORK (GenomeWeb) – UK biotech startup Methuselah Health plans to use analysis of protein post-translational modifications to develop drugs and diagnostics for age-related diseases.

The company, which launched in 2015 but has only recently begun publicizing its work, believes protein PTMs can provide insights into protein damage that can be used to address common late-onset conditions like atherosclerosis, Alzheimer's, and auto-immune disorders, said David Grainger, Methuselah's executive chairman and CEO.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers have treated an X-linked genetic disease affecting three babies in utero, Stat News reports.

The Associated Press reports that the US Centers for Disease Control and Prevention is beefing up sequencing as a tool to investigate foodborne illnesses.

Researchers have sequenced samples from ancient toilets to study past eating habits and health, NPR reports.

In Nature this week: ash dieback disease fungal genome, and more.